BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30912094)

  • 1. Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9.
    Kieckhaefer JE; Maina F; Wells RG; Wangensteen KJ
    Semin Liver Dis; 2019 May; 39(2):261-274. PubMed ID: 30912094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
    Chen Y; Li L; Lan J; Cui Y; Rao X; Zhao J; Xing T; Ju G; Song G; Lou J; Liang J
    Mol Cancer; 2022 Jan; 21(1):11. PubMed ID: 34983546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
    Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
    Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
    Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
    Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform.
    Wangensteen KJ; Wang YJ; Dou Z; Wang AW; Mosleh-Shirazi E; Horlbeck MA; Gilbert LA; Weissman JS; Berger SL; Kaestner KH
    Hepatology; 2018 Aug; 68(2):663-676. PubMed ID: 29091290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.
    Weber J; Öllinger R; Friedrich M; Ehmer U; Barenboim M; Steiger K; Heid I; Mueller S; Maresch R; Engleitner T; Gross N; Geumann U; Fu B; Segler A; Yuan D; Lange S; Strong A; de la Rosa J; Esposito I; Liu P; Cadiñanos J; Vassiliou GS; Schmid RM; Schneider G; Unger K; Yang F; Braren R; Heikenwälder M; Varela I; Saur D; Bradley A; Rad R
    Proc Natl Acad Sci U S A; 2015 Nov; 112(45):13982-7. PubMed ID: 26508638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for HCC target discovery.
    Molina-Sánchez P; Lujambio A
    Aging (Albany NY); 2017 Apr; 9(4):1088-1089. PubMed ID: 28455974
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis.
    Fan Y; Bazai SK; Daian F; Arechederra M; Richelme S; Temiz NA; Yim A; Habermann BH; Dono R; Largaespada DA; Maina F
    J Hepatol; 2019 Mar; 70(3):470-482. PubMed ID: 30529386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the literature on the use of CRISPR/Cas9 gene therapy to treat hepatocellular carcinoma.
    Amjad E; Pezzani R; Sokouti B
    Oncol Res; 2024; 32(3):439-461. PubMed ID: 38361756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of drug-inducible CRISPR-Cas9 systems for large-scale functional screening.
    Sun N; Petiwala S; Wang R; Lu C; Hu M; Ghosh S; Hao Y; Miller CP; Chung N
    BMC Genomics; 2019 Mar; 20(1):225. PubMed ID: 30890156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring liver cancer biology through functional genetic screens.
    Wang C; Cao Y; Yang C; Bernards R; Qin W
    Nat Rev Gastroenterol Hepatol; 2021 Oct; 18(10):690-704. PubMed ID: 34163045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9-based Pten knock-out and Sleeping Beauty Transposon-mediated Nras knock-in induces hepatocellular carcinoma and hepatic lipid accumulation in mice.
    Gao M; Liu D
    Cancer Biol Ther; 2017 Jul; 18(7):505-512. PubMed ID: 28513320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma.
    Chiu AP; Tschida BR; Lo LH; Moriarity BS; Rowlands DK; Largaespada DA; Keng VW
    World J Gastroenterol; 2015 Nov; 21(42):12157-70. PubMed ID: 26576100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine.
    Kampmann M
    ACS Chem Biol; 2018 Feb; 13(2):406-416. PubMed ID: 29035510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy.
    Li L; Yu S; Hu Q; Hai Y; Li Y
    Int J Biol Sci; 2021; 17(12):3133-3144. PubMed ID: 34421355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
    Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
    EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.
    Wei L; Lee D; Law CT; Zhang MS; Shen J; Chin DW; Zhang A; Tsang FH; Wong CL; Ng IO; Wong CC; Wong CM
    Nat Commun; 2019 Oct; 10(1):4681. PubMed ID: 31615983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of genetically tailored porcine liver cancer cells by CRISPR/Cas9 editing.
    Elkhadragy L; Regan MR; M Totura W; Goli KD; Patel S; Garcia K; Stewart M; Schook LB; Gaba RC; Schachtschneider KM
    Biotechniques; 2021 Jan; 70(1):37-48. PubMed ID: 33222517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Charge-reversal nanocomolexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma.
    Nie JJ; Liu Y; Qi Y; Zhang N; Yu B; Chen DF; Yang M; Xu FJ
    J Control Release; 2021 May; 333():362-373. PubMed ID: 33785418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
    Wang F; Hou W; Chitsike L; Xu Y; Bettler C; Perera A; Bank T; Cotler SJ; Dhanarajan A; Denning MF; Ding X; Breslin P; Qiang W; Li J; Koleske AJ; Qiu W
    Gastroenterology; 2020 Jul; 159(1):289-305.e16. PubMed ID: 32171747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.